Title

Long-Term Treatment With rhIGF-1 in GHIS
A Study of Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS)
  • Phase

    Phase 2/Phase 3
  • Study Type

    Interventional
  • Intervention/Treatment

    mecasermin ...
  • Study Participants

    92
The objective of this study was to evaluate the long-term safety and effectiveness of mecasermin (the study drug) in children with growth failure due to severe Primary insulin-like growth factor-1 deficiency (Primary IGFD).
Study Started
May 20
1991
Primary Completion
Dec 15
2011
Study Completion
Dec 15
2011
Results Posted
Jul 06
2023
Last Update
Jul 06
2023

Drug mecasermin

injections BID of rhIGF-1, mecasermin

  • Other names: Increlex

mecasermin, injections BID of rhIGF-1 Experimental

Criteria

Inclusion Criteria:

Height <-2SD for age and gender
IGF-1 <-2SD for age and gender
Evidence of GH resistance

Exclusion Criteria:

closed epiphyses
prior active malignancy
major organ disfunction
treatment with medications that would diminish growth
clinically significant cardiac abnormalities

Summary

Mecasermin

All Events

Event Type Organ System Event Term Mecasermin

Annualized Height Velocity Up to 12 Years

Height velocity is the difference between 2 height measurements, divided by years elapsed between measurements.

Mecasermin

>= 10 years

4.5
centimeter per year (cm/y) (Mean)
Standard Deviation: 2.0

>= 11 years

4.1
centimeter per year (cm/y) (Mean)
Standard Deviation: 2.0

>= 12 years

3.9
centimeter per year (cm/y) (Mean)
Standard Deviation: 2.0

>= 1 year

8.0
centimeter per year (cm/y) (Mean)
Standard Deviation: 2.3

>= 2 years

5.9
centimeter per year (cm/y) (Mean)
Standard Deviation: 1.7

>= 3 years

5.5
centimeter per year (cm/y) (Mean)
Standard Deviation: 1.8

>= 4 years

5.2
centimeter per year (cm/y) (Mean)
Standard Deviation: 1.5

>= 5 years

4.9
centimeter per year (cm/y) (Mean)
Standard Deviation: 1.5

>= 6 years

4.8
centimeter per year (cm/y) (Mean)
Standard Deviation: 1.4

>= 7 years

4.3
centimeter per year (cm/y) (Mean)
Standard Deviation: 1.5

>= 8 years

4.4
centimeter per year (cm/y) (Mean)
Standard Deviation: 1.5

>= 9 years

4.4
centimeter per year (cm/y) (Mean)
Standard Deviation: 1.7

Baseline (Pre-dose)

2.6
centimeter per year (cm/y) (Mean)
Standard Deviation: 1.7

Number of Naive Participants With Height Velocity <5 cm/y at the End of 1 Year of Study Treatment

Height measurements were performed using wall-mounted stadiometers for analysis of growth data.

Mecasermin

Height Velocity Standard Deviation Score Up to 12 Years

Center for disease control growth charts from the US were used as reference for age and gender-dependent mean and standard deviation. Height velocity-standard deviation score was calculated as height velocity minus reference mean height velocity divided by standard deviation of the reference mean height velocity. Greater height velocity standard deviation score indicates better outcome.

Mecasermin

>= 10 years

0.1
Standard deviation score (Mean)
Standard Deviation: 1.6

>= 11 years

0.5
Standard deviation score (Mean)
Standard Deviation: 2.6

>= 12 years

-0.1
Standard deviation score (Mean)
Standard Deviation: 1.5

>= 1 year

1.7
Standard deviation score (Mean)
Standard Deviation: 2.8

>= 2 years

>= 3 years

-0.1
Standard deviation score (Mean)
Standard Deviation: 1.9

>= 4 years

-0.2
Standard deviation score (Mean)
Standard Deviation: 1.9

>= 5 years

-0.3
Standard deviation score (Mean)
Standard Deviation: 1.7

>= 6 years

-0.2
Standard deviation score (Mean)
Standard Deviation: 1.6

>= 7 years

-0.5
Standard deviation score (Mean)
Standard Deviation: 1.7

>= 8 years

-0.2
Standard deviation score (Mean)
Standard Deviation: 1.6

>= 9 years

-0.4
Standard deviation score (Mean)
Standard Deviation: 0.8

Baseline (Pre-dose)

-3.4
Standard deviation score (Mean)
Standard Deviation: 1.6

Height Standard Deviation Score Up to 12 Years

Center for disease control growth charts from the US were used as reference for age and gender-dependent mean and standard deviation. Height standard deviation score was calculated as height minus reference mean height divided by standard deviation of the reference mean height. A higher height standard deviation score indicates a better outcome.

Mecasermin

>= 10 years

-5.0
Standard deviation score (Mean)
Standard Deviation: 1.7

>= 11 years

-4.7
Standard deviation score (Mean)
Standard Deviation: 1.2

>= 12 years

-4.4
Standard deviation score (Mean)
Standard Deviation: 1.3

>= 1 year

-6.1
Standard deviation score (Mean)
Standard Deviation: 1.8

>= 2 years

-5.6
Standard deviation score (Mean)
Standard Deviation: 1.7

>= 3 years

-5.3
Standard deviation score (Mean)
Standard Deviation: 1.7

>= 4 years

-5.1
Standard deviation score (Mean)
Standard Deviation: 1.7

>= 5 years

-5.0
Standard deviation score (Mean)
Standard Deviation: 1.7

>= 6 years

-4.9
Standard deviation score (Mean)
Standard Deviation: 1.6

>= 7 years

-4.9
Standard deviation score (Mean)
Standard Deviation: 1.7

>= 8 years

-5.1
Standard deviation score (Mean)
Standard Deviation: 1.7

>= 9 years

-5.0
Standard deviation score (Mean)
Standard Deviation: 1.6

Baseline (Pre-dose)

-6.9
Standard deviation score (Mean)
Standard Deviation: 1.8

Approximate Increase in Height Over Expected for Naïve Participants With Near-Adult Height

Height measurements were performed using wall-mounted stadiometers for analysis of growth data.

Mecasermin

13.3
cm (Mean)
Standard Deviation: 8.4

Age, Continuous

7.6
years (Mean)
Standard Deviation: 4.3

Race/Ethnicity, Customized

Sex: Female, Male

Overall Study

Mecasermin

Drop/Withdrawal Reasons

Mecasermin